Weight Loss Clinical Trials 2023

Browse 72 Weight Loss Medical Studies Across 54 Cities

1 Phase 3 Trial · 83 Weight Loss Clinics

Reviewed by Michael Gill, B. Sc.
10 Weight Loss Clinical Trials Near Me
Top Hospitals for Weight Loss Clinical Trials
Image of Citruslabs in California.
Citruslabs
Santa Monica
3Active Trials
4All Time Trials for Weight Loss
2023First Weight Loss Trial
Image of Pennington Biomedical Research Center in Louisiana.
Pennington Biomedical Research Center
Baton Rouge
3Active Trials
19All Time Trials for Weight Loss
2001First Weight Loss Trial
Image of Signos in California.
Signos
Palo Alto
2Active Trials
2All Time Trials for Weight Loss
2021First Weight Loss Trial
Image of Brigham and Women's Hospital in Massachusetts.
Brigham and Women's Hospital
Boston
2Active Trials
5All Time Trials for Weight Loss
2020First Weight Loss Trial
Image of Oregon Health and Science University in Oregon.
Oregon Health and Science University
Portland
2Active Trials
2All Time Trials for Weight Loss
2021First Weight Loss Trial
Top Cities for Weight Loss Clinical Trials
Image of Houston in Texas.
Houston
4Active Trials
M D Anderson Cancer CenterTop Active Site
Weight Loss Clinical Trials by Phase of TrialWeight Loss Clinical Trials by Age Group
< 18 Weight Loss Clinical Trials
1Active Weight Loss Clinical Trials
Most Recent Weight Loss Clinical TrialsTop Treatments for Weight Loss Clinical Trials
Treatment Name
Active Weight Loss Clinical Trials
All Time Trials for Weight Loss
First Recorded Weight Loss Trial
Signos digital health app and CGM
2
2
2021
Active Intervention Group
2
2
2016
Online Family Skills Training
1
1
2023
Intervention Group (SlimBiotic Probiotic)
1
1
2023
Time restricted eating and calorie restriction
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Weight Loss
Treatment
Year
Sponsor
Tirzepatide
2021
Eli Lilly and Company
EXCAP©®
2020
University of Rochester
Anamorelin Hydrochloride
2018
Helsinn Healthcare SA
anamorelin HCl
2018
Helsinn Healthcare SA
Orlistat
2018
Emory University

What Are Weight-loss Clinical Trials

Health practitioners commonly advise their patients to lose weight. The CDC found that nearly half of the adults in America tried to reduce their weight in the last twelve months. Yet obesity is on the rise, increasing from 30.5% in 199 to 41.9% in 2020 in the US population.

Consequently, weight-loss is studied in clinical trials look at:

  • Why do people gain weight

  • How can people be better supported to maintain their weight loss

  • If there are medications that could help the brain’s control of appetite

  • Looking at the impact of physical activity

  • If various techniques can help a person lose weight

Why Is Weight-loss Being Studied Through Clinical Trials?

Weight-loss is studied because of obesity’s correlation to other adverse health factors (such as cardiovascular disease and diabetes).

However, as UCLA researchers and other experts have long noted: diets don’t work. Thus, clinical trials examine how drugs and other therapies can help reduce hunger signaling, enabling better appetite regulation.

For instance, there have been many trials, including one by researchers at Inje University in Seoul, Korea, examining the role of oxytocin in weight loss and weight management. However, while an intranasal dose of oxytocin has provided promising results, most studies have focused on males.

What Are The Types Of Treatments Available For Weight-loss?

According to the Mayo Clinic, treatment to lose weight is usually a combination of:

  • Dietary changes
  • Increased exercise and activity
  • Behavior changes, including possibly needing counseling
  • Medication

What Are Some Recent Breakthrough Clinical Trials For Weight-loss?

2023: SURMOUNT-1, Tirzepatide – Researchers for Eli Lilly’s conducted a phase 2 double-blind, randomized trial with over 2,539 adults with a BMI of 30+. For 72 weeks, participants not being given the placebo received a weekly dose of tirzepatide of either 5mg, 10mg, or 15mg.

Patients in the higher dosages lost an average of 52 pounds. In addition, the drug was combined with a diet and exercise program. Those on the placebo but using the same exercise and eating program lost an average of 5 pounds.

2021: Semaglutide – In a study funded by Astellas Pharma, researchers from around the world, including from the University of Liverpool and University College London Center for Obesity Research, examined if adults could lose weight when administered a once-weekly semaglutide dose of 2.4mg.

The double-blind trial involved 1,961 participants. Those given semaglutide had a -14.9% body weight change, whereas the placebo had only a -2.4% change.

2018: SMART Pivotal Trial: Fifteen hospitals in the US participated in testing the Oblon Intragastric Balloons. The Oblong uses gas instead of saline. Of the 711 subjects, 387 received the Obalon Balloon or Sham Device. Participants were then put on a diet and exercise program. Those who received the Obalon lost twice as much as those given a Sham.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 5th, 2023

References1 Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014 Feb 26;311(8):806-14. doi: 10.1001/jama.2014.732. https://pubmed.ncbi.nlm.nih.gov/245702442 Sallis JF, Grossman RM, Pinski RB, Patterson TL, Nader PR. The development of scales to measure social support for diet and exercise behaviors. Prev Med. 1987 Nov;16(6):825-36. doi: 10.1016/0091-7435(87)90022-3. https://pubmed.ncbi.nlm.nih.gov/34322323 Barlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007 Dec;120 Suppl 4:S164-92. doi: 10.1542/peds.2007-2329C. https://pubmed.ncbi.nlm.nih.gov/180556514 Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalová L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001. https://pubmed.ncbi.nlm.nih.gov/265904185 Barlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007 Dec;120 Suppl 4:S164-92. https://pubmed.ncbi.nlm.nih.gov/180556516 Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalova L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001. https://pubmed.ncbi.nlm.nih.gov/265904187 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762. https://pubmed.ncbi.nlm.nih.gov/224887648 Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006 Apr 12;295(14):1681-7. doi: 10.1001/jama.295.14.1681. https://pubmed.ncbi.nlm.nih.gov/166090909 Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006 Apr 12;295(14):1681-7. https://pubmed.ncbi.nlm.nih.gov/1660909010 Spear BA, Barlow SE, Ervin C, Ludwig DS, Saelens BE, Schetzina KE, Taveras EM. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics. 2007 Dec;120 Suppl 4:S254-88. doi: 10.1542/peds.2007-2329F. https://pubmed.ncbi.nlm.nih.gov/18055654